RxDoctor Payments Data

Cesar Romero, MD

Internal Medicine · Hamilton, ALNPI 1003870494

Payments from drug & device makers

$942in general payments, 2019–2025

Across 56 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$222
  • Amgen$193
  • Lilly USA, LLC$84
  • Merck$63
  • Pfizer$56
  • Shield Therapeutics Inc$51
  • plus $274 from 11 others

What the payments were for

  • Food & beverage$942100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$942 in reported general payments places this provider in the 60th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$2,090
Medicare patients
18
Services billed
20

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide236$225,110
EliquisApixaban201$131,236
JardianceEmpagliflozin172$122,554
FarxigaDapagliflozin Propanediol112$95,491
TrulicityDulaglutide89$84,416
JanuviaSitagliptin Phosphate115$52,470
MounjaroTirzepatide31$31,392
EntrestoSacubitril/Valsartan24$20,080
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$17,847
XareltoRivaroxaban36$13,796
MyrbetriqMirabegron12$13,185
Rosuvastatin Calcium693$11,300
RybelsusSemaglutide12$11,271
GemtesaVibegron31$9,724
Esomeprazole Magnesium148$7,903

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$16$236,380248 claims
PfizerEliquis$56$131,236201 claims
Boehringer IngelheimJardiance, Combivent Respimat$40$128,757185 claims
Lilly USA, LLCTrulicity, Mounjaro$84$115,808120 claims
AstraZenecaFarxiga, Symbicort$222$99,812131 claims
MerckJanuvia$63$52,470115 claims
GSKTrelegy Ellipta$40$17,84729 claims
Johnson & JohnsonXarelto$12$13,79636 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Hamilton

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →